Cointime update: China’s National Health Commission, National Healthcare Security Administration, National Administration of Traditional Chinese Medicine and National Disease Control and Prevention Administration issued a joint notice on the safe and rational use of innovative drugs. The notice sets out measures on promoting rational allocation, strengthening training guidance, optimizing use conditions and improving management practices, and clarifies that certain innovative drugs are not counted toward the growth rate of average outpatient drug costs.
China’s Four Agencies Clarify Innovative Drugs Excluded from Outpatient Average Drug Cost Growth
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
2h ago
Bitwise Files S-1 for Spot Zcash ETF on Texas Stock Exchange
2h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
3h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
5h ago
Binance Plans to Enter Five Asian Markets Next Year, Focus on South and Southeast Asia
8h ago
US Senator: Jensen Huang and Commerce Secretary Lutnick Agree to Testify at Committee Hearing
9h ago
Germany nominates Brunnermeier for ECB role, spokesperson confirms